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Objective. Imbalanced cytokine production by T cells characterizes both patients with systemic lupus erythematosus (SLE) and lupus-prone mice and contributes to immune dysregulation. This study was undertaken to further investigate in detail the production of interleukin-2 (IL-2), interferon-g (IFNg), IL-4, and IL-17A by CD41 cell subsets in healthy subjects and patients with SLE, and the signaling response of CD41 T cells in response to exogenous IL-2.
Methods. Cytokine production by differentiated subsets of CD41 T cells was assessed by intracellular staining following stimulation with phorbol myristate acetate and ionomycin and by enzyme-linked immunosorbent assay after anti-CD3/anti-CD28 stimulation. The IL-2 signaling pathway was examined by assessing JAK-3/STAT-5 phosphorylation. Cell proliferation in response to IL-2 was examined by carboxyfluorescein succinimidyl ester dilution.
Results. Production of IL-2 was defective primarily among naive CD41 T cells, whereas the production of IFNg, IL-4, and IL-17A was not significantly different between patients with SLE and healthy subjects. JAK-3/STAT-5 phosphorylation and proliferation of CD41 T cells from SLE patients in response to exogenous IL-2 were impaired compared to cells from healthy subjects.
Conclusion. These data suggest that altered IL-2 production, as well as impaired IL-2-mediated signaling and proliferative responses, characterize SLE CD41 T cells. Our data demonstrate the need for caution in designing IL-2 treatment trials for patients with SLE. Approaches to restore CD41 T cell sensitivity to IL-2 should be considered.
T cells are key players in the pathogenesis of systemic lupus erythematosus (SLE). A defect in interleukin-2 (IL-2) production by T cells is a hallmark of both murine lupus and human SLE (1,2). IL-2 is an important cytokine that is involved in normal T cell activation and has a critical function in the control of peripheral immune responses by promoting activation-induced cell death (a process required for deletion of autoreactive cells) and by favoring differentiation, survival, and function of Treg cells (3, 4) . More importantly, IL-2 plays a significant role in cellmediated immunity against infections, one of the leading causes of morbidity and mortality in patients with SLE (3).
IL-2 signals through the IL-2 receptor (IL-2R), which is composed of 3 chains-CD25 or IL-2Ra, CD122 or IL-2Rb, and the CD132 or IL-2R common g-chain (the latter of which is an essential component of the receptors for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21). Binding of IL-2 to its receptor leads to the activation of JAK-1 and JAK-3, followed by the phosphorylation of the STAT-5A/B transcription factor. Once phosphorylated, STAT-5 translocates to the nucleus and binds to IL-2 target genes, which are mainly involved in T cell growth, proliferation, and differentiation (5).
Low-dose IL-2 treatment is being considered as a therapeutic approach in patients with SLE and other autoimmune diseases (6) (7) (8) (9) . Notwithstanding the impressive response rates in these open-label trials, it is important to understand the response behavior of T cell subsets when exposed to IL-2 (10, 11) . In this study, we investigated cytokine production patterns in subsets of CD41 T cells isolated from the peripheral blood of patients with SLE and healthy subjects. CD41 T cells from SLE patients produced significantly less IL-2 than CD41 T cells isolated from healthy subjects. This defect was more pronounced in the naive CD41 T cell subset compared to the more differentiated subsets (e.g., central memory or effector memory CD41 T cells). Moreover, SLE CD41 T cells responded poorly to recombinant IL-2, manifested by decreased phosphorylation of JAK-3 and STAT-5 and impaired proliferation compared to healthy controls. Our data provide evidence that patients with SLE may respond poorly to IL-2 treatment because of the compromised IL-2/IL-2R/JAK-1/3/STAT-5 pathway.
PATIENTS AND METHODS
Human SLE and control cells. All patients with SLE included in this study (n 5 36) were diagnosed according to the American College of Rheumatology classification criteria (12) . Patients with SLE were recruited from the Division of Rheumatology at Beth Israel Medical Center and provided consent, as approved by the institutional review board. Age-, sex-, and ethnicity-matched healthy individuals were chosen as controls (n 5 37). Disease activity score for the patients with SLE was measured using the SLE Disease Activity Index (SLEDAI) scoring system (13) . Informed consent was obtained and approved by the institutional review board after the nature and possible consequences of the studies were explained, in compliance with the Helsinki Declaration.
Cell isolation. Peripheral blood from the study subjects was collected in lithium heparin tubes. Peripheral blood mononuclear cells (PBMCs) were enriched by density-gradient centrifugation (Lymphocyte Separation Medium; Corning Life Sciences). PBMCs were either used directly or cryopreserved in liquid nitrogen for future experiments. Total CD41 T cells, naive CD41 T cells, and memory CD41 T cells were isolated using a T Cell Isolation Kit II according to the manufacturer's instructions (Miltenyi Biotec).
Assessment of CD41 T cell cytokine production. PBMCs (1 3 10 6 ) were cultured in complete culture medium (RPMI; Corning) (supplemented with 10% fetal bovine serum, 100 mg/ml of streptomycin, and 100 units/ml of penicillin) and stimulated with phorbol 12-myristate 13-acetate (PMA) (25 ng/ml) and ionomycin (0.5 mg/ml) for 6 hours in the presence of brefeldin A (GolgiPlug; BD Biosciences). At the end of stimulation, cells were washed, stained for dead cells using a Zombie Aqua Fixable Viability Kit (BioLegend) (20 minutes at 48C), and then labeled with the following antibodies: Brilliant Violet Horizon 395-conjugated CD3, PerCP eFluor 710-conjugated CD4, PerCP-conjugated CD8, allophycocyanin (APC)-Cy7-conjugated CD45RA, and Alexa Fluor 488-conjugated CCR7 (30 minutes at 48C). Subsequently, cells were permeabilized (20 minutes at 48C) (Cytofix/Cytoperm kit; BD Biosciences), washed twice (Perm/Wash buffer; BD Biosciences), and stained with phycoerythrin (PE)-Cy7-conjugated IL-2, Pacific Blue-conjugated interferon-g (IFNg), Alexa Fluor 647-conjugated IL-17A, and PE-conjugated IL-4 (30 minutes at 48C).
Antibodies were purchased from BD Biosciences, BioLegend, and eBioscience.
Assessment of STAT-5 phosphorylation. CD41 T cells (0.2 3 10 6 ) were stimulated in complete medium in 96-well plates with recombinant IL-2 (PeproTech) for up to 180 minutes. At the end of stimulation, cells were washed, stained for dead cells using a Zombie Aqua Fixable Viability Kit (20 minutes at 48C), washed again, permeabilized, and stained with APC-conjugated (BioLegend) and Alexa Fluor 488-conjugated pSTAT-5 (Cell Signaling Technology) using a Phospho-Epitopes Exposure kit with PerFix Expose, according to the manufacturer's instructions (Beckman Coulter).
Cell proliferation. Carboxyfluorescein succinimidyl ester (CFSE)-labeled naive CD41 T cells (0.2 3 10 6 ) were stimulated for 6 days in complete media in precoated (overnight) 96-well plates with anti-CD3 (0.5 mg/ml) and anti-CD28 (5 mg/ml) with or without recombinant IL-2 (50 IU/ml). At the end of the stimulation, the cells were stained for dead cells using a Zombie Aqua Fixable Viability Kit (20 minutes at 48C). The CFSE dilution was assessed by flow cytometry. Data were acquired on an LSR II SORP (5 lasers [355, 405, 488, 561, 640 nm]; BD Bioscience).
IL-2 enzyme-linked immunosorbent assay (ELISA). Total naive or memory CD41 T cells were isolated and stimulated as described above. After 18 hours, IL-2 in supernatants was measured by ELISA (BioLegend).
Western blotting. Cells were lysed in radioimmunoprecipitation assay buffer supplemented with phosphatase and protease inhibitors (Roche). Proteins were separated in 4-12% gradient Bis-Tris gels (Life Technologies) and transferred to PVDF membrane (Millipore). Membranes were blocked for 1 hour with Tris buffered saline solution containing 0.05% Tween and 5% nonfat dry milk. Membranes were incubated overnight at 48C with the indicated antibody followed by incubation with a horseradish peroxidase-conjugated antibody. Detection was performed with Clarity ECL Western Blotting reagents (Bio-Rad) and visualization with a ChemiDoc XRS1 Molecular Imager (Bio-Rad). Densitometric analysis was performed using ImageJ software (National Institutes of Health).
Statistical analysis. Student's t-test with correction by the Holm-Sidak method was used for statistical comparisons. For multiple comparisons, statistical analysis was performed by one-way analysis of variance followed by post hoc analysis with Tukey's test. Statistical comparison of cytokine-producing CD41 T cell subsets was performed by chi-square test. The programs FlowJo (version X), Spice (version 5.35) (14) , and GraphPad Prism (version 6) were used for analyis.
RESULTS
Reduced number of IL-2-producing CD41 T cells in SLE patients compared to healthy subjects. Circulating differentiated subsets of T cells were evaluated by assessing the expression of the chemokine receptor CCR7 and CD45RA. This allowed us to distinguish 3 subsets of CD41 T cells: naive (CD45RA1CCR71), central memory (CM) (CD45RA-CCR71), and effector memory (EM) (CD45RA-CCR7-) (15) .
We examined the production of IL-2, IL-4, IL-17A, and IFNg by the aforementioned subsets of CD41 T cells following PMA and ionomycin stimulation. The frequency of cytokine-producing cells increased over differentiation status, as IFNg, IL-2, and IL-4 production were augmented over differentiation from naive to CM and to EM (Figure 1) . Production of IL-17A remained low in this experimental setting, as cells were not polarized toward Th17 differentiation before PMA/ionomycin stimulation. 
COMTE ET AL
When we compared patients with SLE to healthy controls, no difference in the frequency of IL-4, IL-17A, and IFNg-producing CD41 T cells was observed. Alternatively, the percentage of IL-2-producing CD41 T cells was reduced in patients with SLE. This decrease was observed in all subsets (naive, CM, EM), but was statistically significant only in the naive CD41 T cell population. We were not able to establish any correlation between the frequency of IL-2-producing cells and SLEDAI score (Figure 2A ), suggesting that compromised production of IL-2 by naive CD41 T cells is a hallmark of SLE that is not affected by its activity.
To confirm these results, we isolated total CD41 T cells, naive CD41 T cells (CD41CD45RA1), and memory CD41 T cells (CD41CD45RA-) from patients with SLE and healthy controls. Cells were stimulated for 18 hours with anti-CD3 and anti-CD28 monoclonal antibodies. Production of IL-2 in the supernatant of the cell culture was assessed by ELISA. We observed a decrease in IL-2 production in all subsets tested ( Figure 2B ). The defect was more pronounced in the naive CD41 T cell population compared to the memory CD41 T cells population ( Figure 2B) .
Impaired response to exogenous IL-2 in CD41 T cells from SLE patients. After observing that IL-2 production was compromised in CD41 T cells from SLE patients, we examined the response of CD41 T cells from SLE patients to exogenous IL-2. To investigate this, we studied the IL-2 signaling pathway in SLE CD41 T cells by measuring STAT-5 phosphorylation in response to IL-2. CD41 T cells from patients and controls were isolated and stimulated with recombinant IL-2. The IL-2/STAT-5 pathway was examined by assessing the frequency of pSTAT-5-positive cells over time. The expression of pSTAT-5 in response to exogenous IL-2 initially increased over time, reached maximum levels after 30 minutes of cell stimulation, and was almost completely abrogated after 3 hours of stimulation ( Figure  3A ). Following stimulation with IL-2, the percentage of pSTAT-51 CD41 T cells from patients with SLE was lower than that in cells from healthy controls. The difference was statistically significant when pSTAT-5 was assessed at 30 and 45 minutes of stimulation ( Figure 3A) .
Differences in STAT-5 phosphorylation between patients with SLE and controls are not a result of diminished IL-2R expression on the CD41 T cells of patients. As we have previously shown, expression of CD25 and CD122 is similar in patients with SLE and controls (16) . In summary, the above data emphasize that the phosphorylation of STAT-5 upon IL-2 stimulation is defective in CD41 T cells isolated from patients with SLE.
Compromised proliferation of CD41 T cells from SLE patients in response to exogenous IL-2. Because the CD41 T cells of patients with SLE display a defective response to exogenous IL-2 in terms of STAT-5 phosphorylation, we examined the proliferation of CD41 T cells in response to anti-CD3/anti-CD28 stimulation with or without exogenous IL-2. CD41 T cells were labeled with CFSE, and proliferation was expressed as the percentage of CFSE-low cells after 6 days of stimulation. In response to exogenous IL-2, the percentage of proliferating CD41 T cells from patients with SLE was significantly reduced compared to that in cells from healthy controls ( Figure 3B) . SLE T cells exhibit reduced JAK-3 phosphorylation in response to IL-2 administration. As described above, CD41 T cells of patients with SLE demonstrate decreased STAT-5 phosphorylation and reduced proliferative responses following stimulation with exogenous IL-2. We sought to further delineate the events that precede STAT-5 activation by assessing phosphorylation of JAK-3 upon stimulation with IL-2. To this end, T cells isolated from the peripheral blood of healthy subjects and patients with SLE were either left unstimulated or stimulated with recombinant IL-2 for 15 minutes or 30 minutes. JAK-3 phosphorylation was examined by Western immunoblotting. The highest levels of JAK-3 phosphorylation were seen after 15 minutes of stimulation. When we treated T cells from patients with SLE with recombinant IL-2, phosphorylation of JAK-3 was significantly lower compared to that in healthy controls (Figures 4A and B) . Reduced JAK-3 phosphorylation was not due to diminished total JAK-3 levels, as we observed no statistically significant differences in the levels of total JAK-3 among patients with SLE and healthy controls ( Figures 4C and D) . Taken together, these data suggest that the CD41 T cells of patients with SLE, and especially naive CD41 T cells, not only display decreased IL-2 production following stimulation, but also demonstrate impaired IL-2 signaling and response.
DISCUSSION
Aberrant cytokine production is a hallmark of immune dysregulation in SLE. Compromised IL-2 production has been consistently described in SLE. In this study, we confirmed that IL-2 production is impaired in T cells from patients with SLE; however, in our cohort, we did not observe any significant differences in the production of IL-4, IL-17A, and IFNg by CD41 T cells.
We further characterized this abnormality by examining IL-2 production by differentiated subsets of CD41 T cells and CD41 T cells. Our data emphasize that IL-2 production is reduced in each differentiated subset of CD41 T cells, and that the defect is more pronounced in the naive CD41 cells. More importantly, this abnormality is associated with a defect in IL-2 signaling (as illustrated by reduced JAK-3 phosphorylation), leading to decreased phosphorylation of STAT-5, a downstream transcription factor in the IL-2 signaling pathway. At a functional level, we also observed decreased CD41 T cell proliferation in response to recombinant IL-2. Moreover, disease activity has little or no effect on compromised IL-2 production, suggesting that the IL-2 defect is a primary defect in SLE, as already apparent in naive CD41 T cell populations.
Recent reports from uncontrolled clinical trials emphasize that administration of low-dose IL-2 could be beneficial in SLE (7) (8) (9) . In this context, our results suggest that strategies aimed at restoring IL-2 sensitivity of CD41 T cells (for example, through increasing the expression of IL-2R on the CD41T cell surface [15] ), should be considered in conjunction with low-dose IL-2 treatment, because CD41 T cell display not only decreased IL-2 production, but also a defective response to IL-2.
